Patients with CDI also had more severe acute graft vs. host disease than those without CDI.
News
Advertisement
The hematologist and oncologist from the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center discussed unmet needs with CAR T-cell therapy in multiple myeloma.
Advertisement
The hematologist and oncologist from University of California, San Francisco discussed the current state of cellular therapy in multiple myeloma.
The new technologies were made available as a result of the licensing agreement between MD Anderson and Bellicum Pharmaceuticals.
Lineage Cell Therapeutics announced promising data from interim results of the phase 1/2a clinical trial assessing the cell therapy.
The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.
Advertisement
Review top news and interview highlights from the week ending September 17, 2021.
An interim analysis has met prespecified safety and efficacy checkpoints.
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed his research into the mechanisms of the BET protein family and T cells.
The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed his team’s research in the role of HTRA1.
Advertisement
Paul Rennert, president and chief scientific officer of Aleta BioTherapeutics, discussed the company’s research on CAR T therapies.
A phase 1/2a clinical trial assessing VOR33 is currently enrolling.
Researchers are exploring gene-independent therapeutic strategies to circumvent the challenges of gene-replacement therapies.
The chief executive and chief medical officers of Celyad Oncology discussed the company’s future research and plans.
Following a voluntary pause, a patient experiencing a liver AE has died and the trial is now on clinical hold.
TVGN-489 is an investigational allogeneic cytotoxic CD8+ T lymphocyte therapy that may help prevent breakthrough COVID infection.
Jan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s cell therapy platforms.
RGX-314 is being developed to target wet AMD, diabetic retinopathy, and other chronic retinal diseases.
The associate professor from The University of Texas MD Anderson Cancer Center discussed the integration of CAR T-cell therapy into the treatment paradigm of R/R MM.
The company is currently evaluating ALLOB, its investigational cell therapy product for bone regeneration.
The hematologist and oncologist from City of Hope discussed the utility of CAR T cells in patients with hematologic cancers.
Paul Lammers, MD, MSc, president and chief executive officer, Triumvira Immunologics, discussed the company’s T-cell antigen coupler technology.
A new TIL therapy seeks to improve on current treatments for metastatic non-small cell lung cancer such as PD-1 inhibitors.
The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells.
A single-dose gene therapy for uveitis could fill an important treatment gap for patients.
The chief executive and medical officers of Cytovia Therapeutics discussed their natural killer cell therapy technology.
Decibel Therapeutics previously presented favorable preclinical data at ASGCT 2021.
Michael Singer, MD, PhD, chief scientific officer, Cartesian Therapeutics, discussed the company’s RNA Armory technology.
The professor and director of the myeloma center at the University of Arkansas for Medical Sciences discussed future research with CAR T in multiple myeloma.
Adoptive transfer of TILs elicited an ORR of 56% in patients with metastatic melanoma who were naïve to PD-1 inhibitors compared with 24% in patients refractory to PD-1 inhibitors.
